Drug Development Focus: Samsung Bioepis Launches Byooviz in Europe
Monday, 5 January 2026, 01:12
Samsung Bioepis Commences Commercialisation of Byooviz
In a notable feat for drug development, Samsung Bioepis has officially launched its biosimilar, Byooviz, in Europe. This biosimilar serves as a medical alternative to Genentech’s esteemed Lucentis (ranibizumab), enhancing patient access to necessary treatments.
Impact of Byooviz on Drug Development
- Byooviz aims to provide cost-effective treatment for eye conditions.
- This launch reflects ongoing improvements in drug development initiatives globally.
- Increasing competition in the pharmaceutical market can lead to lower prices and better accessibility.
This launch underscores ongoing commitments to advancing drug development and improving healthcare outcomes.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.